Dr. Urbanic is actively involved in national cooperative group trials sponsored by the Alliance and NRG Networks and serves as the PI (or co-PI) of multiple cooperative group trials. He has had two notable projects finish in the past year, including CALGB 31102 a multi-institutional Phase I trial of hypofractionated radiotherapy combined with chemotherapy for locally advanced lung cancer.
He has also served as CALGB co-chair on N107c evaluating the role of brain radiosurgery after resection of brain metastasis and is the national radiation oncology co-chair on RTOG Foundation 3505 which is looking at the use of consolidative nivolumab for stage 3 lung cancer. He will be the radiation oncology co-chair on the Alliance Foundation trial exploring the use of ne-adjuvant and consolidative immunotherapy with atezolizumab in locally advanced lung cancer treated with chemoradiotherapy.
Recruited from Wake Forest University in 2014, Dr. James Urbanic joins the Department as an Associate Professor and Associate Division Chief for Clinical Trials in the Division of Clinical and Translational Research. He is actively involved in national cooperative group trials sponsored by the Alliance and NRG Networks. He serves as the PI (or co-PI) of multiple cooperative group trials including CALGB 31102 and RTOG 1328, both focusing on concomitant chemoradiotherapy in locally advanced lung cancer. Dr. Urbanic is also the UC San Diego Proton Center Medical Director.